Streamline Health Solutions (STRM) Q4 2025 Earnings Call May 02, 2025 09:00 AM ET Company Participants Jacob Goldberger - VP - FinanceBen Stilwill - President & CEOBryant Reeves - Chief Financial OfficerNeil Cataldi - Principal Operator As a reminder, this conference is being recorded. It is now my pleasure to introduce Jacob Goldberger, Vice President of Finance. Thank you. You may begin. Jacob Goldberger Thank you for joining us for the corporate update and financial results review of Streamline Health So ...

COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for VIMKUNYA® (recombinant, adsorbed) for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older. The vaccine was approved following MHRA review under the international recognition procedure, which is a targeted assessment that recognize ...

A review of recent findings suggests that Appili’s biodefense vaccine, ATI-1701, may have a role in preventing tularemia outbreaksHALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia, a potentially lethal bacterial inf ...

Conference Call and Webcast at 8:30 AM Eastern TimeNEW YORK, April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, inclu ...

Core Points - Valneva SE's chikungunya vaccine IXCHIQ has faced updated recommendations from France's Haute Autorité de Santé (HAS) due to serious adverse events reported in elderly individuals with comorbidities during the vaccination campaign in La Reunion and Mayotte [1][2] - The French health authorities have suspended the use of IXCHIQ for individuals aged 65 and older while maintaining its recommendation for those aged 18 to 64 [2] - Valneva has supplied 40,000 doses of IXCHIQ to La Reunion amid a significant chikungunya outbreak with approximately 40,000 confirmed cases since the start of 2025 [1][4] Company Overview - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, addressing unmet medical needs [7] - The company has a strong track record in advancing vaccines from early research and development to approvals, currently marketing three proprietary travel vaccines [8] - Valneva's revenues from its commercial business support the advancement of its vaccine pipeline, which includes candidates for Lyme disease, Shigella, Zika virus, and other public health threats [9] Industry Context - Chikungunya virus (CHIKV) is a mosquito-borne disease that has been identified in over 110 countries, with significant medical and economic burdens expected to grow due to climate change [6] - The World Health Organization (WHO) has recognized chikungunya as a major public health problem, highlighting the need for effective vaccines and interventions [6]

NO LONGER ONLY AVAILABLE FOR LARGE CARRIERS, PROVIDERS CAN NOW SIGN UP TO OFFER THE MOEN® FLO SMART WATER MONITOR AND SHUTOFF TO POLICYHOLDERS AT NO COSTNORTH OLMSTED, Ohio, April 14, 2025 /PRNewswire/ -- Moen, a leader in water experiences in the home, has launched an Insurance Partner Program for insurance providers of all sizes, including regional carriers, to help limit water damage claims across all states with its Moen® Flo Smart Water Monitor and Shutoff. Water damage is a leading cause of insurance ...

Core Insights - Terminix has released its annual list of the Top 50 Most Mosquito-Infested Cities in the U.S. based on 2024 service data from over 300 branches nationwide [1][2] Group 1: Rankings and Locations - California and Texas dominate the rankings, with Los Angeles ranked as the most mosquito-infested city, followed by Dallas (2), New York City (3), Atlanta (4), and Houston (5) [2][4] - Other cities that ranked high include Philadelphia, Washington, D.C., Orlando, and San Francisco, indicating a widespread mosquito problem across the country [2] Group 2: Public Health Implications - Mosquitoes are not only a nuisance but also pose significant public health risks due to their ability to carry diseases [2][3] Group 3: Prevention Tips - Terminix recommends several mosquito prevention strategies, including adding mosquito traps, removing standing water, and using EPA-registered repellents [5][7] - The company emphasizes the importance of an integrated mosquito management plan that combines multiple tactics to control mosquito populations [7] Group 4: Company Overview - Rentokil Terminix is a leading provider of pest management services in North America, offering solutions for various pests including mosquitoes [6] - The company is part of Rentokil Initial plc, one of the largest business services companies globally [6]

Core Viewpoint - Theriva Biologics is presenting interim blinded safety and pharmacokinetic data for SYN-004 at the ESCMID Global Congress, focusing on its potential to prevent acute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients [1][3]. Group 1: Clinical Trial Details - The ongoing Phase 1b/2a clinical trial is randomized, double-blinded, and placebo-controlled, evaluating the safety and tolerability of oral SYN-004 in allogeneic HCT recipients receiving IV antibiotics [3]. - The trial is being conducted at Washington University School of Medicine and aims to enroll up to 36 participants across three cohorts, each receiving different IV beta-lactam antibiotics [3]. - Safety and pharmacokinetic data are reviewed by an independent Data and Safety Monitoring Committee to determine the progression to the next cohort [3]. Group 2: About SYN-004 - SYN-004 (ribaxamase) is designed to degrade certain IV beta-lactam antibiotics in the gastrointestinal tract, maintaining gut microbiome balance and preventing Clostridioides difficile infection and acute graft-versus-host disease [4][6]. - A previous Phase 2b clinical trial with 412 patients showed that SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis, leading to better maintenance and recovery of the microbiome [4]. Group 3: Company Overview - Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, with a subsidiary working on an oncolytic adenovirus platform [5][6]. - The company's lead candidates include VCN-01, SYN-004, and SYN-020, targeting various aspects of cancer treatment and microbiome protection [6].

Core Insights - Valneva SE and LimmaTech Biologics AG have initiated a Phase 2 infant safety and immunogenicity study for Shigella4V2 (S4V2), a tetravalent bioconjugate vaccine candidate against shigellosis, marking a significant step in vaccine development [1][3][4] Industry Overview - Shigellosis is the second leading cause of fatal diarrheal disease globally, with an estimated 165 million infections annually, of which 62.3 million occur in children under five years [2][6] - The disease results in approximately 600,000 deaths each year, highlighting the urgent need for an effective vaccine [6] Study Details - The Phase 2 study (Identifier: NCT06523231) will involve around 110 nine-month-old infants to determine the optimal vaccine dosage for future Phase 3 trials [3] - The study is randomized, controlled, and blinded, taking place at a single site in Kenya, with results expected in the second half of 2025 [3] Company Statements - Dr. Juan Carlos, Chief Medical Officer of Valneva, emphasized the unacceptable mortality rates from shigellosis and the company's commitment to developing vaccines for unmet medical needs [4] - Dr. Patricia Martin, COO of LimmaTech, highlighted the trial's initiation as a significant milestone in their collaboration with Valneva to address this global health threat [4] Regulatory Status - The U.S. FDA has granted Fast Track designation to S4V2, recognizing its potential to address a serious health condition and fill an unmet medical need [5]

Core Insights - LexisNexis Risk Solutions has appointed Glenn Prager as Executive Director of Government Risk Solutions to enhance program integrity and protect public funds [1][2] - Prager brings over two decades of experience in combating fraud, waste, and abuse, focusing on ensuring that benefits reach those in need [1][2] - The company aims to modernize fraud prevention efforts using advanced technology and innovative strategies under Prager's leadership [3] Company Overview - LexisNexis Risk Solutions utilizes data and advanced analytics to help businesses and government entities reduce risk and improve decision-making [4] - The company provides solutions across various industries, including insurance, financial services, healthcare, and government [4] - LexisNexis Risk Solutions is part of RELX, a global provider of information and analytics for professional and business customers [4]